The company reported revenues of $470.3 million, down from $478.2 million in Q4 2015 but beating the average analysts' estimate of $464.5 million.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
The firms will work to implement MALDI PharmaPulse high-throughput mass spec instrumentation at AMRI's Integrated Drug Discovery Center.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Bruker said it plans to use InVivo assets to explore antibody enrichment methods that could eliminate the need for culturing prior to MALDI-based microbial ID.
Bioyong will invest in test development as well as validation, regulatory approval, and commercialization in China and, possibly, other Asia-Pacific countries.
The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.
The company said Scils will bolster its MALDI imaging offerings while InVivo will help with development of new content for its MALDI Biotyper business.
The company recently acquired intellectual property and personnel to drive development of PCR tests for applications including syndromic microbiology testing.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.
An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.
The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.
In Nature this week: genotypes linked to hip osteoarthritis, and more.